| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
| Sales | 26,612 | 29,437 | 13,657 | 2,559 | 196 |
| Sales Growth | -9.60% | +115.55% | +433.69% | +1,205.61% | +2,350.00% |
| Net Income | -1,124 | -1,834 | -4,700 | -3,764 | -10,047 |
| Net Income Growth | +38.71% | +60.98% | -24.87% | +62.54% | -0.94% |
Innocan Pharma Corp (INNO.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
InnoCan Pharma Corp is a engaged in the development, manufacture, and marketing of cosmetic products. The company has two segments: Online sales - Sky Global operations, which engages in the development of non-CBD personal care and beauty products in the United States for online platforms such as Amazon, and other e-commerce retail sales. Other operations - the development of several drug delivery platforms, combining cannabinoids with other pharmaceutical ingredients as well as the development and sale of CBD-integrated topical products.
Fiscal Year End Date: 12/31